A Phase II Randomized Clinical Trial of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
significant effect rate (the proportion of G4 and G5, graded by Miller & Payne Method); null effect rate (the proportion of G1 and G2)
within the first 14 days (plus or minus 3 days) after surgery
No
Tianfeng Wang, Doctor
Study Chair
Beijing Cancer Hospital Breast Center
China: Food and Drug Administration
B04
NCT00919880
July 2009
December 2010
Name | Location |
---|